BABISWARUP REDDY CHANDAMURI M.D.
Prescription History 1104140144
Internal Medicine - Gastroenterology in Houma, LA

NPI Status: Active since March 19, 2010

Contact Information

1990 INDUSTRIAL BLVD
HOUMA, LA
ZIP 70363
Phone: (985) 868-9300
Fax: (985) 851-0053

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for BABISWARUP REDDY CHANDAMURI M.D., an active Gastroenterology specialist practicing in Houma, LA. Our medical registry currently tracks 13 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 874 documented patient claims. Among these therapy options, the most frequently utilized medication is Epclusa, which accounts for 296 claims alone.


Azathioprine

Generic Formulation: AzathioprineSpecialty: Gastroenterology
Provider Metrics Summary
Total Claims 18
30-Day Fills 26.0
Days Supply 780
LA State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills44.2
Peer Average Days Supply1,320
Conservative Utilization

This provider writes prescriptions for this formulation 30.8% less frequently than the standard regional baseline metric for practitioners inside LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,254.62 across this reporting matrix range.

Provider Avg Cost Per Claim

$69.70

State Avg Cost Per Claim

$60.72

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed)

Therapeutic Applications

Azathioprine is used to prevent organ rejection in people who have received a kidney transplant. It is usually taken along with other medications to allow your new kidney to function normally. Azathioprine is also used to treat rheumatoid arthritis. In this condition, the body's defense system (immune system) attacks healthy joints. Azathioprine belongs to a class of drugs known as immunosuppressants. It works by weakening the immune system to help your body accept the new kidney as if it were your own (in the case of an organ transplant) or to prevent further damage to your joints (in the case of rheumatoid arthritis). Talk to your doctor about the risks and benefits of azathioprine, especially when used by children and young adults.

Dicyclomine Hcl

Generic Formulation: Dicyclomine HclSpecialty: Gastroenterology
Provider Metrics Summary
Total Claims 67
30-Day Fills 92.7
Days Supply 2,765
LA State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills42.3
Peer Average Days Supply1,063
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 116.1% higher than the standard regional baseline profile for LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,860.40 across this reporting matrix range.

Provider Avg Cost Per Claim

$27.77

State Avg Cost Per Claim

$17.94

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Diphenoxylate-Atropine

Generic Formulation: Diphenoxylate Hcl/AtropineSpecialty: Gastroenterology
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 405
LA State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills22.9
Peer Average Days Supply343
Conservative Utilization

This provider writes prescriptions for this formulation 36.4% less frequently than the standard regional baseline metric for practitioners inside LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $607.25 across this reporting matrix range.

Provider Avg Cost Per Claim

$43.38

State Avg Cost Per Claim

$25.27

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat diarrhea. It helps to decrease the number and frequency of bowel movements. It works by slowing the movement of the intestines. Diphenoxylate is similar to opioid pain relievers, but it acts mainly to slow the gut. Atropine belongs to a class of drugs known as anticholinergics, which help to dry up body fluids and also slow gut movement. This medication should not be used to treat diarrhea caused by certain types of infection (such as C. difficile-associated diarrhea following antibiotic therapy). Talk to your doctor for more details. This medication is not recommended for use in children younger than 6 years due to an increased risk of serious side effects (such as breathing problems).

Epclusa

Generic Formulation: Sofosbuvir/VelpatasvirSpecialty: Gastroenterology
Provider Metrics Summary
Total Claims 296
30-Day Fills 296.0
Days Supply 8,288
LA State Average Benchmarks
Peer Average Claims39.0
Peer Average 30-Day Fills39.5
Peer Average Days Supply1,106
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 659.0% higher than the standard regional baseline profile for LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,866,258.48 across this reporting matrix range.

Provider Avg Cost Per Claim

$26,575.20

State Avg Cost Per Claim

$26,717.44

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is a combination of sofosbuvir and velpatasvir and is used to treat chronic (long-lasting) hepatitis C, a viral infection of the liver. It may sometimes be used with another antiviral medication (ribavirin). These drugs work by reducing the amount of hepatitis C virus in your body, which helps your immune system fight the infection and may help your liver recover. Chronic hepatitis C infection can cause serious liver problems such as scarring (cirrhosis), or liver cancer. It is not known if this treatment can prevent you from passing the virus to others. Do not share needles, and practice safer sex (including the use of latex condoms) to lower the risk of passing the virus to others.

Gavilyte-C

Generic Formulation: Peg3350/Sod Sulf,bicarb,cl/KclSpecialty: Gastroenterology
Provider Metrics Summary
Total Claims 17
30-Day Fills 17.0
Days Supply 17
LA State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills30.5
Peer Average Days Supply34
Conservative Utilization

This provider writes prescriptions for this formulation 43.3% less frequently than the standard regional baseline metric for practitioners inside LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $241.81 across this reporting matrix range.

Provider Avg Cost Per Claim

$14.22

State Avg Cost Per Claim

$15.69

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

PEG (polyethylene glycol) with electrolyte is used to clean out the intestines before certain bowel exam procedures such as colonoscopy or barium enema X-rays. It is a laxative that works by drawing large amounts of water into the colon. This effect results in watery bowel movements. Clearing stool from the intestines helps your doctor to better examine the intestines during your procedure.

Harvoni

Generic Formulation: Ledipasvir/SofosbuvirSpecialty: Gastroenterology
Provider Metrics Summary
Total Claims 149
30-Day Fills 149.0
Days Supply 4,172
LA State Average Benchmarks
Peer Average Claims57.0
Peer Average 30-Day Fills57.3
Peer Average Days Supply1,603
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 161.4% higher than the standard regional baseline profile for LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $5,067,724.90 across this reporting matrix range.

Provider Avg Cost Per Claim

$34,011.58

State Avg Cost Per Claim

$33,501.46

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is a combination of ledipasvir and sofosbuvir and is used to treat chronic (long-lasting) hepatitis C, a viral infection of the liver. It may sometimes be used with another antiviral medication (ribavirin). These drugs work by reducing the amount of hepatitis C virus in your body, which helps your immune system fight the infection and may help your liver recover. Chronic hepatitis C infection can cause serious liver problems such as scarring (cirrhosis), or liver cancer. It is not known if this treatment can prevent you from passing the virus to others. Do not share needles, and practice safer sex (including the use of latex condoms) to lower the risk of passing the virus to others.

Humira Pen

Generic Formulation: AdalimumabSpecialty: Gastroenterology
Provider Metrics Summary
Total Claims 40
30-Day Fills 40.0
Days Supply 1,124
LA State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills20.0
Peer Average Days Supply559
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 110.5% higher than the standard regional baseline profile for LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $565,230.24 across this reporting matrix range.

Provider Avg Cost Per Claim

$14,130.76

State Avg Cost Per Claim

$8,640.01

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A humanized monoclonal antibody that binds specifically to TNF-ALPHA and blocks its interaction with endogenous TNF RECEPTORS to modulate INFLAMMATION. It is used in the treatment of RHEUMATOID ARTHRITIS; PSORIATIC ARTHRITIS; CROHN'S DISEASE and ULCERATIVE COLITIS.

Therapeutic Applications

Adalimumab is used to reduce pain and swelling due to certain types of arthritis (such as rheumatoid, psoriatic, juvenile idiopathic, ankylosing spondylitis). This medication is also used to treat certain skin disorders (such as plaque-type psoriasis, hidradenitis suppurativa). It works by blocking a protein (tumor necrosis factor or TNF) found in the body's immune system that causes joint swelling and damage in arthritis as well as red scaly patches in psoriasis. Adalimumab belongs to a class of drugs known as TNF blockers. By reducing joint swelling, this medication helps to reduce further joint damage and preserve joint function. Adalimumab is also used to treat certain bowel conditions (Crohn's disease, ulcerative colitis) and a certain eye disease (uveitis).

Humira(Cf) Pen

Generic Formulation: AdalimumabSpecialty: Gastroenterology
Provider Metrics Summary
Total Claims 19
30-Day Fills 19.0
Days Supply 532
LA State Average Benchmarks
Peer Average Claims43.0
Peer Average 30-Day Fills44.5
Peer Average Days Supply1,248
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 55.8% less volume than the regional standard for practitioners inside LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $238,951.17 across this reporting matrix range.

Provider Avg Cost Per Claim

$12,576.38

State Avg Cost Per Claim

$8,345.05

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A humanized monoclonal antibody that binds specifically to TNF-ALPHA and blocks its interaction with endogenous TNF RECEPTORS to modulate INFLAMMATION. It is used in the treatment of RHEUMATOID ARTHRITIS; PSORIATIC ARTHRITIS; CROHN'S DISEASE and ULCERATIVE COLITIS.

Therapeutic Applications

Adalimumab is used to reduce pain and swelling due to certain types of arthritis (such as rheumatoid, psoriatic, juvenile idiopathic, ankylosing spondylitis). This medication is also used to treat certain skin disorders (such as plaque-type psoriasis, hidradenitis suppurativa). It works by blocking a protein (tumor necrosis factor or TNF) found in the body's immune system that causes joint swelling and damage in arthritis as well as red scaly patches in psoriasis. Adalimumab belongs to a class of drugs known as TNF blockers. By reducing joint swelling, this medication helps to reduce further joint damage and preserve joint function. Adalimumab is also used to treat certain bowel conditions (Crohn's disease, ulcerative colitis) and a certain eye disease (uveitis).

Motegrity

Generic Formulation: Prucalopride SuccinateSpecialty: Gastroenterology
Provider Metrics Summary
Total Claims 15
30-Day Fills 21.0
Days Supply 630
LA State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills27.0
Peer Average Days Supply775
Conservative Utilization

This provider writes prescriptions for this formulation 31.8% less frequently than the standard regional baseline metric for practitioners inside LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $11,402.79 across this reporting matrix range.

Provider Avg Cost Per Claim

$760.19

State Avg Cost Per Claim

$604.17

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat chronic constipation. It is used when other medications used to treat constipation (such as laxatives) have not provided relief. Prucalopride works by improving how well your stomach and intestines move food through the bowels during digestion.

Pantoprazole Sodium

Generic Formulation: Pantoprazole SodiumSpecialty: Gastroenterology
Provider Metrics Summary
Total Claims 144
30-Day Fills 366.0
Days Supply 10,931
LA State Average Benchmarks
Peer Average Claims111.0
Peer Average 30-Day Fills214.8
Peer Average Days Supply6,345
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 29.7% more claims than the standard regional baseline profile for LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,871.30 across this reporting matrix range.

Provider Avg Cost Per Claim

$19.94

State Avg Cost Per Claim

$12.80

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.

Therapeutic Applications

Pantoprazole is used to treat certain stomach and esophagus problems (such as acid reflux). It works by decreasing the amount of acid your stomach makes. This medication relieves symptoms such as heartburn, difficulty swallowing, and cough. It helps heal acid damage to the stomach and esophagus, helps prevent ulcers, and may help prevent cancer of the esophagus. Pantoprazole belongs to a class of drugs known as proton pump inhibitors (PPIs).

Sod Sulf-Potass Sulf-Mag Sulf

Generic Formulation: Sodium, Potassium,mag SulfatesSpecialty: Gastroenterology
Provider Metrics Summary
Total Claims 58
30-Day Fills 58.0
Days Supply 100
LA State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills25.9
Peer Average Days Supply45
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 132.0% higher than the standard regional baseline profile for LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,523.05 across this reporting matrix range.

Provider Avg Cost Per Claim

$77.98

State Avg Cost Per Claim

$81.32

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Sodium/potassium/magnesium sulfate solution is used to clean out the intestines before a certain bowel exam procedure (colonoscopy). It is a laxative that works by drawing large amounts of water into the colon. This causes watery bowel movements. Clearing stool from the intestines helps your doctor to better examine the intestines during your procedure.

Stelara

Generic Formulation: UstekinumabSpecialty: Gastroenterology
Provider Metrics Summary
Total Claims 25
30-Day Fills 26.0
Days Supply 733
LA State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills34.4
Peer Average Days Supply1,010
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $683,882.01 across this reporting matrix range.

Provider Avg Cost Per Claim

$27,355.28

State Avg Cost Per Claim

$26,428.86

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A humanized monoclonal antibody that binds to IL-12 and IL-23 and is used as a DERMATOLOGIC AGENT in the treatment of patients with plaque PSORIASIS who have not responded to other therapies.

Therapeutic Applications

Ustekinumab is used to treat plaque psoriasis, a certain type of arthritis (psoriatic arthritis), or certain bowel conditions (Crohn's disease, ulcerative colitis). It works by blocking certain natural proteins in your body (interleukin-12 and interleukin-23) that cause inflammation (swelling) in these conditions. Ustekinumab does not cure these diseases, but helps to lessen symptoms of the disease. It can help to decrease the amount of plaques in plaque psoriasis, decrease the number of swollen/painful joints in psoriatic arthritis, and decrease symptoms such as abdominal pain/cramping and diarrhea in Crohn's disease and ulcerative colitis.

Vemlidy

Generic Formulation: Tenofovir AlafenamideSpecialty: Gastroenterology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
LA State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills32.5
Peer Average Days Supply973
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 62.5% less volume than the regional standard for practitioners inside LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $17,952.03 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,496.00

State Avg Cost Per Claim

$1,390.42

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Tenofovir alafenamide is used to treat chronic hepatitis B infection, a viral infection of the liver. It works by stopping or slowing the growth of the virus. Chronic hepatitis infection can lead to serious liver damage (cirrhosis) and liver cancer. It is not known if tenofovir alafenamide can cure hepatitis B or can prevent you from passing the virus to others. Practice safer sex (such as the use of latex condoms) to lower the risk of passing the virus to others.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like BABISWARUP REDDY CHANDAMURI M.D. provides transparency into local medical care patterns within Houma, LA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Gastroenterology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.